The 42-year-old woman had no evidence of cancer after receiving dostarimab, a drug still in early trials to treat a rare form of colorectal cancer.
advertisementCarrie Downey, a single mother with a 17-year-old son, was diagnosed with colon cancer a year ago, but after just six months of treatment with a new anti-cancer drug, she is now fully recovered.
The drug, dostarlimab, is currently in clinical trials and targets certain colorectal cancers that have genetic abnormalities in their cells. All patients have specific mismatch repair (MMR) gene mutations.
According to Swansea Bay University Health Board, this genetic defect is present in 3.5% to 5% of rectal cancers.
Ms Downey, 42, was told that depending on the location of the cancer, she might be left with a permanent stoma. A stoma is an opening in the abdomen through which the body’s waste products are expelled, collected in a small bag worn outdoors. body.
She was referred to oncologist Dr Craig Barrington on behalf of South West Wales Cancer Centre.
“He said something like, ‘What would you do if I told you that you could get the same results without having a permanent stoma or major surgery and no evidence of cancer?'” Downey said. said in a statement:
“He tested my biopsy and knew I had this rare mutation. He asked me if I wanted to go ahead with it.”
Downey received intravenous (IV) treatments of the drug three times a week for six months, with each treatment taking about 30 minutes.
“I was tired and had a rash here and there, but it was nothing compared to chemotherapy, radiation and surgery,” she said.
The tumor shrank during treatment and no evidence of disease remained at the end of the period.
Mr Barrington said in a statement: “We are the first country in the UK, and together with Italy, in the world, to routinely include it as a treatment option.”
“It doesn’t mean patients have to have it. It’s an additional tool in the toolbox, so to speak. But when a trial shows a 100 percent complete response, it’s hard to argue against that.”
Medicine is still in clinical trials, but data is limited
Dostarlimab has been prescribed to 10 patients in Wales, but its use in the treatment of these rare rectal cancers is still being analyzed.
The drug, sold by GlaxoSmithKline (GSK) as Gemperi, was first approved in the European Union in 2021 to treat the condition. endometrial cancer It is advanced and has the same genetic abnormality.
A small clinical trial of 12 patients with rectal cancer in the United States revealed that New England Medical Journal In 2022, all patients were found to have had a complete clinical response.
The study concluded that this type of rectal cancer, known as mismatch repair-deficient/high microsatellite instability (dMMR/MSI-H), is “highly sensitive” to drugs, but “symptomatically Longer-term follow-up is needed to evaluate.” Duration of reaction”.
There are further ongoing trials in the United States, but these are “single-arm trials” and therefore not randomized, which was cited as a cause for concern by U.S. authorities in February.
Nevertheless, the U.S. Food and Drug Administration (FDA) committee concluded that data from two single-arm trials “characterized the benefits and risks” of using this drug to treat advanced rectal cancer with genetic abnormalities. They voted that it was “enough to
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
I have been reading out some of your articles and i can state pretty clever stuff. I will surely bookmark your website.
Grateful, but let’s not make a big deal out of it.
This blog was… how do you say it? Relevant!! Finally I’ve found something which helped me. Thanks a lot.
As an alternative, this time he slunk – if you possibly can image a winter fattened bull slinking – out from underneath the fence.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
|Hello to all, for the reason that I am actually keen of
Isn’t it entertaining if we always talk about topics like that.’~~;~
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
FIM Group’s mentors, include Benjamin Graham, Sir John Templeton and Warren Buffett, because they are the past century’s most notable basic stocks and bonds buyers.
May I simply say what a relief to discover somebody who really knows what they are talking about online. You certainly know how to bring an issue to light and make it important. More and more people must look at this and understand this side of the story. It’s surprising you are not more popular given that you definitely have the gift.
Very good post! We will be linking to this great article on our site. Keep up the great writing.
Good post. I’m experiencing a few of these issues as well..
Fantastic beat ! I would like to apprentice while you amend your website, how can i subscribe for a blog website? The account aided me a acceptable deal. I had been a little bit acquainted of this your broadcast provided bright clear concept
Great wordpress blog here.. It’s hard to find quality writing like yours these days. I really appreciate people like you! take care
qOcgyLKpx4o
Hello just wanted to give you a quick heads up and let you know a few of the pictures aren’t loading correctly. I’m not sure why but I think its a linking issue. I’ve tried it in two different browsers and both show the same outcome.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Introducing to you the most prestigious online entertainment address today. Visit now to experience now!
She was a resident of Fairfield for 20 years.
Hi, the whole thing is going sound here and ofcourse every one is sharing data, that’s truly excellent,keep up writing.
) Vou voltar a visitá-lo uma vez que o marquei no livro. O dinheiro e a liberdade são a melhor forma de mudar, que sejas rico e continues a orientar os outros.
Saved as a favorite, I really like your blog.
Thanks for sharing your info. I truly appreciate your effortsand I am waiting for your next post thank you once again.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Well-written and insightful! Your points are spot on, and I found the information very useful. Keep up the great work!
) Vou voltar a visitá-lo uma vez que o marquei no livro. O dinheiro e a liberdade são a melhor forma de mudar, que sejas rico e continues a orientar os outros.
What i do not understood is in truth how you are not actually a lot more smartlyliked than you may be now You are very intelligent You realize therefore significantly in the case of this topic produced me individually imagine it from numerous numerous angles Its like men and women dont seem to be fascinated until it is one thing to do with Woman gaga Your own stuffs nice All the time care for it up
Can I simply say what a comfort to find an individual who genuinely knows what they are discussing on the internet. You certainly know how to bring an issue to light and make it important. A lot more people really need to read this and understand this side of the story. I was surprised you aren’t more popular since you certainly have the gift.
Introducing to you the most prestigious online entertainment address today. Visit now to experience now!
muito dele está a aparecer em toda a Internet sem o meu acordo.
Appreciate the recommendation. Let me try it out.
Thank you for the good writeup. It in fact was a amusement account it. Look advanced to more added agreeable from you! By the way, how could we communicate?
I love what you guys are usually up too. Such clever work and exposure! Keep up the fantastic works guys I’ve included you guys to my own blogroll.
pokračovat v tom, abyste vedli ostatní.|Byl jsem velmi šťastný, že jsem objevil tuto webovou stránku. Musím vám poděkovat za váš čas